Nanologica AB NICA

Stockholm | Biotech
Follow Nanologica free Follow free

Email when the signal or risk changes · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Updated: 16 Sep 2026 Base analysis: 26 Jan 2026

The news check keeps the assessment current.

General analysis — not personal advice.

HOLD Partly clear

Wait/hold until the company delivers 1–2 quarters of stable underlying operating performance and cash flow from the combined CDMO platform. Watch Q2 (27 Aug) for organic trends, integration costs, and order intake.

The Q2 report showed strong revenue growth but continued negative cash flow and liquidity risk, supporting retention of the HOLD signal until profitability and cash flow stabilize.

Market sentiment Negative ↓
Trend: Declining

Sentiment remains pressured by concerns over cash position and the need for order conversion in H2.

Risk assessment High
Dilution: High
Jurisdiction: Low
Execution: High
Cash flow: 3 mo

HOLD is the call. Negative is the market mood. High risk means a lot can go wrong.

Latest change
  • 1 Sep 2026 — Report released 31 August showed growth from Syntagon acquisition but weaker result and cash, triggering the share drop.

The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.

Show all changes (6) — follow the company free
Type: Biotech
Next report (Q3)
26 Nov 2026
Bull case

Syntagon integration can drive higher capacity utilization and profitability in H2 2026 if the sales organization delivers.

Bear case

Low cash and negative operating cash flow increase the risk of further capital needs before the business reaches break-even.

Why this signal

The Q2 report showed strong revenue growth but continued negative cash flow and liquidity risk, supporting retention of the HOLD signal until profitability and cash flow stabilize.

Recent news
  • The period after 1 September is marked by continued share price decline to 0.32 SEK on 14 September without new press releases. Redeye published a Q2 update and an Analyst Q&A in early September highlighting liquidity concerns but also strategic inventory ahead of order conversion.

Key figures

Revenue
Q2 2026
SEK 24.3M
Revenue TTM
H1 2026
SEK 45.8M
Net income
Q2 2026
SEK -18.7M
Cash
Q2 2026
SEK 19.1M
Shares outstanding
Q1 2026
329M
EPS
Q2 2026
SEK -0.06
Exchange
Stockholm
Type
Biotech
Nanologica AB NICA
Nanologica — this picture changes. Follow free
Follow Nanologica free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.